Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report. Eur Respir J.2017;49(3). pii: 1700214. doi:10.1183/13993003.00214-2017
   Web of Science ®Google Scholar
• Global strategy for the diagnosis, management and prevention of chronic, obstructive pulmonary disease; 2017 Available from: http://goldcopd.org. Accessed June 1, 2019.
   Google Scholar
• Johannessen A, Nilsen RM, Storebø M, et al. Comparison of 2011 and 2007 global initiative for chronic obstructive lung disease guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med. 2013;188(1):51–59. doi:10.1164/rccm.201212-2276OC23590268
   PubMed Web of Science ®Google Scholar
• Soriano JB, Lamprecht B, Ramirez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Repir Med. 2015;3:443–450. doi:10.1016/S2213-2600(15)00157-5
   PubMed Web of Science ®Google Scholar
• Menezes AM, Wehrmeister FC, Perez-Padilla R, et al. The PLATINO study: description of the distribution, stability, and mortality according to the global initiative for chronic obstructivve lung disease classification from 2007 to 2017. Int J Chron Obstcut Pulm Dis. 2017;12:1491–1501. doi:10.2147/COPD.S136023
   PubMed Web of Science ®Google Scholar
• Gedebjerg A, Szepligeti SK, Wackerhausen L-MH, et al. A cohort study: prediction of mortality in patients with chronic obstructive pulmonary disease with the new global initiative for chronic obstructive lung disease 2017 classification. Lancet Respir Med. 2018;6:p204--2012. doi:10.1016/S2213-2600(18)30002-X
   Web of Science ®Google Scholar
• Sorheim IC, Johannessen A, Grydeland TB, et al. Case-control studies on risk factors for chronic obstructive pulmonary disease: how does the sampling of the cases and controls affects the reults? Clin Respir J. 2010;4:89–96. doi:10.1111/j.1752-699X.2009.00154.x20565482
   PubMed Web of Science ®Google Scholar
• Johannessen A, Skorge TD, Bottai M, et al. Mortality by level of emphysema and airway wall thickness. Am J Respir Crit Care Med. 2013;187:602–608. doi:10.1164/rccm.201209-1722OC23328525
   PubMed Web of Science ®Google Scholar
• Grydeland TB, Thorsen E, Dirksen A, et al. Quantitative CT measures of emphysema and airway wall thickness are relatied to D(L)C0. Respir Med. 2011;105:343–351. doi:10.1016/j.rmed.2010.10.01821074394
   PubMed Web of Science ®Google Scholar
• Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative computed tomography measure of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med. 2010;181:353–359. doi:10.1164/rccm.200907-1008OC19926869
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Global Initiative for Chronic Obstructive Lung Disease, et al. Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 176;2007:532–555. doi:10.1164/rccm.200703-456SO17507545
   PubMed Web of Science ®Google Scholar
• Rosa F, Guillaune N, Joan RB, et al. Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. Respir Med. 2018;141:14–19. doi:10.1016/j.rmed.2018.06.01530053959
   PubMed Web of Science ®Google Scholar
• Lopez DCC, Macario DCC, Trigo DMMM, et al. Comparison of 2017 and 2015 global initiative for obstructive lung disease:impact on grouping and outcomes. Am J Res Crit Care Med. 2018;197(4):463–469. doi:10.1164/rccm.201707-1363OC
   Web of Science ®Google Scholar
• Celli BR, Snider GL, Heffner J, et al. Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77–S120.7582322
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Miravtiles M, Norbert M et al. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruc Pulmon Dis. 2017;12:2891–2908. doi:10.2147/COPD.S139470
   PubMed Web of Science ®Google Scholar
• Flynn RWV, MacDonald TM, Chalmers JD, Schembri S. The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respir Res. 2018;19:249. doi:10.1186/s12931-018-0960-330541559
   PubMed Web of Science ®Google Scholar
• Morales DR, Flynn R, Zhang J, Trucco E, Quint JK, Zutis K. External validation of ADO, DOSE, COTE and CODEX at predicting death in primary care patients with COPD using standard and machine learning approaches. Respir Med. 2018;138:150–155. doi:10.1016/j.rmed.2018.04.00329724388
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB, D’Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–172. doi:10.1002/sim.292917569110
   PubMed Web of Science ®Google Scholar
• Soriano JB, Alfageme I, Almagro P, et al. Distributionn and prognostic validity of the new global initiative for chronic obstructive lung disease grading classification. Chest. 2013;143(U39):694–702. doi:10.1378/chest.12-105323187891
   PubMed Web of Science ®Google Scholar
• Nishimura M. Lessons for COPD from the GOLD 2017 report. Respirology. 2017;22:621. doi:10.111/resp.1303828370887
   PubMedGoogle Scholar
• Goossens LM, Leimer I, Metzdorf N, et al. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014;14:163. doi:10.1186/1471-2466-14-16325326750
   PubMed Web of Science ®Google Scholar